Study Need and Importance: Intralesional collagenase Clostridium histolyticum (CCH) is an approved nonsurgical treatment for Peyronie's disease that results in significant improvements in penile curvature and symptom-associated bother. There is a projected workforce shortage within urology, and geographic proximity is an important barrier to health care. We sought to evaluate the geographic distribution of clinical sites offering CCH throughout the United States. What We Found: We identified significant geographic variation in the distribution of approved CCH clinical sites (n [ 23,888; see Figure). The average number of sites offering CCH per state was 47. When we broke this down by state population, there were notable differences. States with the highest ratio of CCH sites per 100,000 residents included Georgia (1.28), Rhode Island (1.13), and Alaska (1.10), whereas New Mexico (0.10), Maine (0.22), and Delaware (0.30) had the lowest ratios. We also looked at availability relative to the number of urologists. States with the highest ratio of CCH sites to total urologists included Georgia (0.37), Alaska (0.31), and Utah (0.30), whereas New Mexico (0.03), Maine 133 (0.05), and Vermont (0.06) had the lowest ratio.